AnnJi Pharmaceutical Co., Ltd. (TPEX:7754)

Market Cap	5.18B +41.0%
Revenue (ttm)	959.00K -96.0%
Net Income	-405.97M
EPS	-4.23
Shares Out	94.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	136,850
Open	55.10
Previous Close	55.00
Day's Range	55.10 - 55.10
52-Week Range	39.15 - 71.20
Beta	-0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About AnnJi Pharmaceutical

AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7754

Financial Performance

In 2025, AnnJi Pharmaceutical's revenue was 7.55 million, a decrease of -92.17% compared to the previous year's 96.45 million. Losses were -357.87 million, 1.10% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 19, 2026

Data Sources Report a data error